Candida albicans

Novotech Publishes Candidiasis and Rheumatoid Arthritis Clinical Trial Landscape Reports to Support Biotech Research Planning

Retrieved on: 
Monday, February 12, 2024
Therapy, Woman, Compound annual growth rate, Gene editing, Rheumatoid arthritis, APA, MicroRNA, Research, Investment, Molecular medicine, Candida albicans, Epidemiology, Geography, Death, Prevalence, Lead, Contract research organization, Joint, Organization, SWOT analysis, Optimism, Clinical trial, Diagnosis, Fungal infection, Disease-modifying antirheumatic drug, Pharmaceutical industry

The Novotech research analyst team provides these expert reports on a monthly basis, completely free of charge.

Key Points: 
  • The Novotech research analyst team provides these expert reports on a monthly basis, completely free of charge.
  • These reports offer current insights into global clinical trial activity, revealing which regions experience the highest trial volumes and the factors behind these trends.
  • The Rheumatoid Arthritis (RA)– Global Clinical Trial Landscape report looks at the prevalence globally and identifies the key factors driving this condition.
  • Overall, this report provides vital insights into the global clinical trial landscape, detailing ongoing developments in RA research.

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Oteseconazole, Vaginal discharge, Red, Candidiasis, Capsule, Irritation, CYP, Fluconazole, Yeast, Patient, National Medical Products Administration, Azole, Enzyme, FDA, Candida albicans, Excipient, Dyspareunia, Vaginal yeast infection, Hypersensitivity, Combustion, Fissure, CYP51, Woman, Pharmaceutical industry

DURHAM, N.C., Feb. 7, 2024 /PRNewswire/ -- Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC). VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.

Key Points: 
  • VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.
  • "The disease burden in China is significant, and access to VIVJOA provides health care providers and women suffering with severe VVC a new treatment option."
  • Vulvovaginal candidiasis is an exceedingly common mucosal infection usually caused by Candida albicans but can occasionally be caused by other Candida species or yeasts.
  • In April 2022, the U.S. Food and Drug Administration (FDA) approved VIVJOA (oteseconazole) Capsules as the first medication for Recurrent Vulvovaginal Candidiasis (RVVC, or chronic yeast infection).

T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing

Retrieved on: 
Wednesday, January 3, 2024
Candida tropicalis, Food, FDA, Candidiasis, Disease, Mortality, Blood, Candida glabrata, Candida krusei, Bambino, Candida albicans, Candida parapsilosis, Patient, Diagnosis, Journal, Blood culture

The T2Candida Panel is the only FDA-cleared diagnostic test able to detect sepsis-causing Candida pathogens directly from blood, in just 3-5 hours, without the need to wait days for a positive blood culture.

Key Points: 
  • The T2Candida Panel is the only FDA-cleared diagnostic test able to detect sepsis-causing Candida pathogens directly from blood, in just 3-5 hours, without the need to wait days for a positive blood culture.
  • The T2Candida Panel runs on the FDA-cleared T2Dx® Instrument and simultaneously detects five Candida species – including Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei, and Candida glabrata.
  • The study also found a higher detection rate with the T2Candida Panel as six additional probable or possible fungal bloodstream infections in pediatric patients were detected by the T2Candida Panel and missed by blood culture.
  • T2Candida was the only test recommended for individual use as a tool for the diagnosis of invasive candidiasis in at-risk children and adolescents.

EFE Introduces a Fresh Take on Reading Glasses with Quantum Technology- A Stylish Leap Forward for Vision and Comfort

Retrieved on: 
Tuesday, January 2, 2024
Heat, Klebsiella pneumoniae, Collection, Glasses, Salmonella, Somatosensory system, Staphylococcus aureus, EFE, Candida albicans, System, Bacteria, Escherichia coli, Comfort, Microscope

Blending the classic functionality of traditional reading glasses with the groundbreaking advancements of quantum technology, we are delivering an exceptional visual experience to our users.

Key Points: 
  • Blending the classic functionality of traditional reading glasses with the groundbreaking advancements of quantum technology, we are delivering an exceptional visual experience to our users.
  • We have expertly combined the usefulness of conventional reading glasses with the innovative capabilities of quantum technology.
  • This fusion offers an enhanced visual experience, taking a important leap forward for vision and comfort.
  • A Touch of Beauty in Every Look- In addition to being savvy, EFE reading glasses also care about appearance!

EFE Introduces Quantum Glasses: Pioneering the Future of Eyewear

Retrieved on: 
Saturday, December 16, 2023
Radiation protection, Klebsiella pneumoniae, Lens, Salmonella, Health, Staphylococcus aureus, Dry, Prescription, EFE, Klebsiella, Temperature, Escherichia, Escherichia coli, Candida albicans, Growth, System, Bacteria, Telescopic sight

New York, Dec. 15, 2023 (GLOBE NEWSWIRE) -- In a landmark innovation, EFE, the renowned eyewear brand from the Netherlands, proudly announces the launch of Quantum Glasses .

Key Points: 
  • New York, Dec. 15, 2023 (GLOBE NEWSWIRE) -- In a landmark innovation, EFE, the renowned eyewear brand from the Netherlands, proudly announces the launch of Quantum Glasses .
  • Crafted to meet the growing challenges of the digital era, Quantum Glasses represent a monumental leap in eyewear technology, offering unprecedented protection and enhancement for eyes frequently exposed to digital screens.
  • Quantum Glasses are a revolutionary product designed to combat the adverse effects of prolonged exposure to digital screens.
  • Unlike traditional blue light-blocking glasses, these glasses incorporate advanced features that go beyond simply alleviating digital eye strain.

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Retrieved on: 
Tuesday, October 24, 2023
Yeast, TIMM, European Confederation, IV, Antimalarial medication, Auris, Candida albicans, Biotechnology, Congress, Professor, ECMM, Mouse, Candida auris, University of Graz, University, Medical Mycology, Fungal infection, Patient, Associate, Mycology, Pharmaceutical industry

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.

Key Points: 
  • JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.
  • “We are excited to see the progress in the development of this novel compound from the fungerp family,” said Dr. Martin Hoenigl, FECMM, Associate Professor of Translational Mycology at University of Graz, Austria and president of the European Confederation of Medical Mycology (ECMM).
  • Results illustrated the potent and broad-spectrum in vitro activity of SCY-247, including against a large array of yeasts, molds and dimorphic fungi.
  • Results also demonstrated SCY-247’s extensive tissue distribution in mice, including brain penetration.

PathogenDx Launches the Cannabis Industry's First AOAC Certified Rapid Semi-Quantification Test for Total Yeast and Mold with Results in a Single-Shift

Retrieved on: 
Wednesday, October 11, 2023
Health, 3D, SM, Real-time, Mold, DNA, Safety, Cannabis, TYM, PTM, Sensor, D3, Octa, AOAC, Quant, Golovinomyces, Drug, Candida albicans, Penicillium, Botrytis, Aspergillus, Cladosporium

New Assay Offers Automated Triplicate Testing, Extended Semi-Quantitation to 100,000 CFU/gram and Fastest Results to Market in One Efficient Test

Key Points: 
  • With just one sample - which can be prepared manually or through PathogenDx's easy-to-use Octa platform - labs can now run every test under PathogenDx's catalog in tandem.
  • "We are proud to launch the new, AOAC certified version of QuantX Fungal, the only test in the market currently providing semi-quantitative analysis of total yeast, mold and fungal species detection," said PathogenDx Co-founder and CEO, Milan Patel .
  • With the dynamic range extended from 1,000 to 100,000 CFU/gram, and triplicate testing of yeast, mold and fungal species all in one test, QuantX Fungal rapidly and accurately quantifies the Total Yeast & Mold responsible for the vast majority of fungal outbreaks.
  • This results in a faster and much more accurate test than qPCR or other technologies.

Nanorobotics System Presents New Options for Targeting Fungal Infections

Retrieved on: 
Monday, July 31, 2023
Infection, Oxygen, Candida albicans, Antifungal, Innovation, Global health, Fungus, Drug resistance, ROS, Motion, Reactive oxygen species, Water, University of Pennsylvania School of Engineering and Applied Science, World Health Organization, Field line, Antibiotics, Environmental remediation, Vaccine, Advanced Materials

They achieved this by using electromagnetic fields to control the shape and movements of these nanozyme microrobots with great precision.

Key Points: 
  • They achieved this by using electromagnetic fields to control the shape and movements of these nanozyme microrobots with great precision.
  • However, the pioneering element of these nanozyme assemblies was their strong binding affinity to fungal cells.
  • Its precise targeting, rapid action suggest potential for treating other types of stubborn infections.
  • "We've uncovered a powerful tool in the fight against pathogenic fungal infections," Koo says.

New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu

Retrieved on: 
Thursday, July 27, 2023
Male, Vaginitis, 1E5, Nonresistance, Urine, COVID-19, Infection, Health equity, Gonorrhea, Candida albicans, Woman, Candidiasis, FACOG, Trichomonas, NPA, STI, Lods, Dicarboxylic acid, Patient, NG, Point-of-care testing, IVD, Chlamydia, Diagnosis, POC, PPA, Talis, Female, Medical imaging, Birth control, Medical device, Antibiotics

REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS) today announced new data supporting the development of its planned CT/NG/TV and vaginal infection panels. Results from these studies, presented in poster sessions at the 2023 IDSOG Annual Meeting in Denver, Colorado, support Talis Biomedical’s mission to advance health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.

Key Points: 
  • “The COVID-19 pandemic accelerated the development of numerous molecular point-of-care platforms to bring rapid respiratory testing closer to patients.
  • Unfortunately, very few are designed to effectively address the needs of women’s and sexual health,” said Rob Kelley, chief executive officer at Talis Biomedical.
  • In females, CT and TV were detected in 19/20 contrived vaginal swab samples at concentrations of 1 IFU/mL and 5 cells/mL, respectively.
  • LODs will be confirmed once a fully developed vulvovaginal candidiasis assay is integrated on the Talis One test cartridge.

T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

Retrieved on: 
Thursday, July 20, 2023
Canker, Candida tropicalis, Fungal infection, Candida albicans, CDC, Candida auris, Therapy, Instrument, Candida krusei, Patient, Blood, Candida glabrata, Candida parapsilosis, Mortality, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Auris, Pharmaceutical industry

LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s Candida auris (C. auris) direct-from-blood molecular diagnostic test.

Key Points: 
  • LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s Candida auris (C. auris) direct-from-blood molecular diagnostic test.
  • This marks the third T2 Biosystems’ product to receive FDA Breakthrough Device designation, as the Company was previously granted FDA Breakthrough Device designation for its T2Resistance® Panel and T2Lyme™ Panel.
  • "We are pleased with the FDA’s decision to grant Breakthrough Device designation for our Candida auris test, which provides greater and more frequent access to the FDA and may accelerate our path to FDA clearance,” stated John Sperzel, Chairman and CEO of T2 Biosystems.
  • The T2Candida Panel runs on the fully-automated T2Dx Instrument and simultaneously detects five Candida species, including Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei, and Candida glabrata.